Welcome to CSNpharm! For Research Use Only!
MDM2
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN23123 | SP 141 | 1253491-42-7 | SP-141 is a MDM2 inhibitor. It acts by exerting excellent in-vitro and in-vivo anticancer activity. |
| CSN18271 | SJ-172550 | 431979-47-4 | SJ-172550 is a small molecule inhibitor of MDMX and competes for the wild type p53 peptide binding to MDMX with an EC50 of 5 M |
| CSN17669 | SAR405838 | 1303607-60-4 | SAR405838 is a highly potent and selective MDM2 inhibitor binds to MDM2 with Ki 088 nM and has high specificity over other proteins |
| CSN17676 | RO8994 | 1309684-94-3 | RO8994 is a highly potent and selective series of spiroindolinone small-molecule MDM2 inhibitor with IC50 of 5 nM HTRF binding assays and 20 nM MTT proliferation assays |
| CSN16216 | RG7388 | 1229705-06-9 | RG7388 is a potent and selective p53MDM2 inhibitor which can block the binding of MDM2 to p53 with IC50 value of 30 nM |
| CSN16567 | RG7112 | 939981-39-2 | RG7112 is a small-molecule MDM2 antagonist which can occupy the p53-binding pocket of MDM2 |
| CSN19741 | PK11195 | 85532-75-8 | PK11195 is a 2Phenylindolylglyoxylyldipeptide Murine Double Minute2 MDM2Translocator Protein TSPOHuman Constitutive Androstane Receptor hCAR Inhibitor and is potentially useful for the Treatment of Gliomas |
| CSN27264 | peptide C19 | 2413879-97-5 | p53/MDM2 peptide C19 is a stapled peptide targeting p53/MDM2 interaction which could increase p53 activity. Its activity and toxicity is highly dependent on the match-up with a specific peptide sequence variant. |
| CSN19111 | NVP-CGM097 Stereoisomer | 2070009-54-8 | NVP-CGM097 stereoisomer is a stereoisomer of NVP-CGM097 |
| CSN17682 | NVP-CGM097 | 1313363-54-0 | NVP-CGM097 is a potent selective and species specific p53-Mdm2 inhibitor with IC50 of 1701 nM |
| CSN12388 | Nutlin 3(Random Configuration) | 890090-75-2 | Nutlin 3Random Configuration is an MDM2 antagonist which can activate p53 pathway through inhibition of p53-MDM2 interaction |
| CSN17157 | Nutlin 3b | 675576-97-3 | Nutlin 3b is a MDM2p53 antagonist or inhibitor with IC50 of 136 M |
| CSN17156 | Nutlin 3a | 675576-98-4 | Nutlin 3a is an improved MDM2-p53 interation antagonist thus acting as p53 (TP53) activator and stabilizer. It is a more potent diastereoisomer of Nutlin-3. |
| CSN18807 | Nutlin 3 | 548472-68-0 | Nutlin 3 is an MDM2 antagonist which can activate p53 pathway through inhibition of p53-MDM2 interaction |
| CSN20477 | NSC 66811 | 6964-62-1 | NSC 66811 is a potent MDM2 inhibitor with Ki value of 120 nM which can disrupt MDM2-p53 interaction and activate p53 function |
| CSN17369 | NSC 59984 | 803647-40-7 | NSC 59984 is a reactivator of p53 which targets various mutant p53 to restore wild-type p53 pathway via the activation of p73 in cancer cells It could induce p53 mutant protein degradation via MDM2-mediated ubiquitination |
| CSN18894 | MX69 | 1005264-47-0 | MX69 is a dual inhibitor of MDM2 and XIAP which can induce MDM2 downregulation resulted not only in inhibition of XIAP expression but also in activation of p53 |
| CSN26108 | MD-224 | 2136247-12-4 | MD-224 is a potent small-molecule MDM2 degrader which induces rapid degradation of MDM2 at concentrations <1 nM in human leukemia cells. |
| CSN22088 | NVP-HDM 201 | 1448867-41-1 | HDM201 binds to the p53 binding-site of the Mdm2 protein disrupting the interaction of the two proteins and leading to the activation of the p53 pathway It induces robust p53-dependent cell cycle arrest and apoptosis in human p53 wild-type tumor cells HDM201 exhibits highly selectivity across a panel of cancer cell lines |
| CSN21087 | DS-3032b | 2095625-97-9 | DS-3032b is an orally available MDM2 (murine double minute 2) antagonist with potential antineoplastic activity. |
| CSN22923 | AQ-101 | 1353384-61-8 | AQ-101 is a inhibitor of MDM2, which induces MDM2 protein degradation through a self-ubiquitination and proteasome-mediated mechanism. |
| CSN19254 | APG-115 | 1818393-16-6 | APG-115 is a compound with a very high affinity to MDM2 Ki 1 nM potent cellular activity and an excellent oral pharmacokinetic profile |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
